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Introduction
Testing for HIV tropism is recommended before pre-
scribing a chemokine receptor blocker. To date, in most
European countries HIV tropism is determined using a
phenotypic test. Recently, new data have emerged sup-
porting the use of a genotypic HIV V3-loop sequence
analysis as the basis for tropism determination. The Eur-
opean guidelines group on clinical management of HIV-
1 tropism testing was established to make recommenda-
tions to clinicians and virologists.
Methods
We searched online databases for articles from Jan 2006
until March 2010 with the terms: tropism or CCR5-
antagonist or CCR5 antagonist or maraviroc or vicri-
viroc. Additional articles and/or conference abstracts
were identified by hand searching. This strategy identi-
fied 712 potential articles and 1240 abstracts. All were
reviewed and finally 57 papers and 42 abstracts were
included and used by the panel to reach a consensus
statement.
Results
The panel recommends HIV-tropism testing for the fol-
lowing indications: i) drug-naïve patients in whom toxi-
city or limited therapeutic options are foreseen; ii)
patients experiencing therapy failure whenever a treat-
ment change is considered. Both the phenotypic
Enhanced Trofile assay (ESTA) and genotypic
population sequencing of the V3-loop are recommended
for use in clinical practice. Although the panel does not
recommend one methodology over another it is antici-
pated that genotypic testing will be used more fre-
quently because of its greater accessibility, lower cost
and shorter turnaround time. The panel also provides
guidance on technical aspects and interpretation issues.
If using genotypic methods, triplicate PCR amplification
and sequencing testing is advised using the G2P inter-
pretation tool (clonal model) with an FPR of 10%. If the
viral load is below the level of reliable amplification,
proviral DNA can be used, and the panel recommends
performing triplicate testing and use of an FPR of 10%.
If genotypic DNA testing is not performed in triplicate
the FPR should be increased to 20%.
Conclusions
The European guidelines on clinical management of
HIV-1 tropism testing provide an overview of current
literature, evidence-based recommendations for the clin-
ical use of tropism testing and expert guidance on unre-
solved issues and current developments. Current data
support both the use of genotypic population sequen-
cing and ESTA for co-receptor tropism determination.
For practical reasons genotypic population sequencing is
the preferred method in Europe.
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